Avoro Capital Advisors LLC Purchases 1,705,556 Shares of uniQure N.V. $QURE

Avoro Capital Advisors LLC lifted its position in shares of uniQure N.V. (NASDAQ:QURE) by 38.4% in the 4th quarter, Holdings Channel reports. The fund owned 6,150,000 shares of the biotechnology company’s stock after buying an additional 1,705,556 shares during the quarter. uniQure accounts for approximately 1.4% of Avoro Capital Advisors LLC’s holdings, making the stock its 18th largest position. Avoro Capital Advisors LLC owned about 0.10% of uniQure worth $147,170,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. ExodusPoint Capital Management LP bought a new position in uniQure in the 4th quarter worth about $1,765,000. Ashford Capital Management Inc. bought a new position in uniQure in the 4th quarter worth about $239,000. Graham Capital Management L.P. bought a new position in uniQure in the 4th quarter worth about $216,000. Sofinnova Investments Inc. boosted its stake in uniQure by 379.6% in the 4th quarter. Sofinnova Investments Inc. now owns 176,513 shares of the biotechnology company’s stock worth $4,224,000 after purchasing an additional 239,651 shares during the period. Finally, MML Investors Services LLC bought a new position in uniQure in the 4th quarter worth about $812,000. Institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on QURE shares. Leerink Partners restated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. HC Wainwright cut their target price on uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, Wolfe Research started coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.83.

uniQure Stock Performance

Shares of QURE opened at $26.99 on Wednesday. The company has a market cap of $1.70 billion, a PE ratio of -7.76 and a beta of 0.98. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average price of $22.93 and a 200-day moving average price of $21.75. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, equities analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jack Kaye sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the transaction, the director directly owned 25,996 shares of the company’s stock, valued at approximately $703,451.76. This trade represents a 7.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Leonard E. Post sold 1,993 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director directly owned 35,494 shares in the company, valued at approximately $960,467.64. This represents a 5.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 85,817 shares of company stock worth $2,232,383. Company insiders own 4.65% of the company’s stock.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.